Drive Wealth Management LLC Invests $916,000 in Aligos Therapeutics, Inc. (NASDAQ:ALGS)

Drive Wealth Management LLC purchased a new stake in Aligos Therapeutics, Inc. (NASDAQ:ALGS) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 23,000 shares of the company’s stock, valued at approximately $916,000.

Separately, AlphaMark Advisors LLC grew its stake in shares of Aligos Therapeutics by 1,000.0% in the fourth quarter. AlphaMark Advisors LLC now owns 1,100 shares of the company’s stock valued at $44,000 after acquiring an additional 1,000 shares in the last quarter. 60.43% of the stock is owned by institutional investors and hedge funds.

Aligos Therapeutics Price Performance

Shares of NASDAQ ALGS opened at $30.43 on Monday. The stock has a market capitalization of $109.18 million, a PE ratio of -2.28 and a beta of 2.50. Aligos Therapeutics, Inc. has a fifty-two week low of $6.76 and a fifty-two week high of $46.80. The business has a fifty day moving average price of $32.24 and a two-hundred day moving average price of $18.86.

Aligos Therapeutics (NASDAQ:ALGS) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($3.07) earnings per share for the quarter, missing the consensus estimate of ($2.15) by ($0.92). The firm had revenue of $1.27 million for the quarter, compared to the consensus estimate of $1.00 million. Aligos Therapeutics had a negative return on equity of 114.34% and a negative net margin of 1,283.19%. During the same period in the prior year, the company earned ($10.25) EPS. On average, equities analysts expect that Aligos Therapeutics, Inc. will post -10.36 EPS for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $75.00 price objective on shares of Aligos Therapeutics in a report on Thursday, November 7th.

Aligos Therapeutics Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).